Post-earnings recap
Reported
Thu, Apr 30, 2026
EPS actual
$1.15
EPS est.
$1.05
EPS surprise
+9.73%
1-day move
+5.29%
Illumina's earnings report showed a strong performance on EPS, exceeding expectations by nearly 10%. This positive surprise likely contributed to the stock's 5.3% increase in value following the announcement. However, the lack of revenue data and management commentary leaves some uncertainty about the company's overall performance and future direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.15 | $1.05 | +9.73% |
| Revenue | N/A | $1.1B | N/A |
No transcript is on record, and the analysis is based on numerical results only.
Illumina, Inc. is a leading company in the health care sector, specializing in life sciences tools and services. They are known for their advanced DNA sequencing technology, which plays a crucial role in genetic research and personalized medicine.
Last quarter
In the last quarter, Illumina reported an EPS of $1.35, exceeding estimates by 7.4%. Despite this positive surprise, the stock saw a slight decline the following day.
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+11.64%
Avg 1-day reaction
+1.98%
Analysts are generally optimistic about Illumina's upcoming earnings, expecting solid performance based on previous trends. The consensus EPS estimate is $1.05, with revenue expected to be stable at $1.1 billion.
Bull case
If Illumina beats earnings expectations again, it could reinforce investor confidence and lead to a positive stock reaction, similar to past performance.
Bear case
On the other hand, if the company fails to meet expectations, it could trigger a negative reaction, especially given the high implied volatility in the options market.
Key metrics to watch
EPS
$1.05Earnings per share is a key indicator of the company's profitability and performance relative to expectations.
Revenue
$1.1BRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will Illumina achieve an EPS of $1.05 or higher?
This figure is critical as it will indicate whether the company is maintaining its growth trajectory and meeting investor expectations.
Q2
What are the revenue figures for the quarter?
Revenue performance will provide insights into market demand for Illumina's products and overall business health.
—
Est. EPS
$1.94
Est. Rev
$3.0B
Impl. Move
±9.9%
Why consensus could be wrong
The Street may be underestimating Illumina's ability to leverage its recent technological advancements for higher revenue growth this quarter.
Supporting evidence
Illumina has consistently beaten EPS estimates in the past, suggesting a pattern of underestimation.
The options market is pricing in a significant move, indicating that traders expect a more pronounced reaction than historical averages suggest.
Key risk
If revenue growth significantly exceeds expectations, it could shift market sentiment dramatically.
Pre-commit to what would confirm each case.
The market is closely watching Illumina's ability to sustain its earnings growth amidst competitive pressures in the life sciences sector.
Bull confirmed if
An EPS of $1.10 or higher would confirm strong demand and operational efficiency.
Bear confirmed if
An EPS below $1.00 would raise concerns about the company's growth and market position.
What the market is pricing for the move.
Implied Move
±9.89%
Historical Avg
±3.4%
The options market is pricing in a significant potential move, suggesting that investors are anticipating volatility around the earnings announcement.
Options are pricing ±9.9% while ILMN has averaged ±3.4% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
31.0%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 7 of 23 (30%)
This setup has occurred 30 times across Health Care in the last 2 years. 16 of 23 (70%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 4.2%, with a raw directional average of +0.6% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
106.39%
of float
Insider
0.21%
of float
Holders
1,327
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
19,191,398 sh · $5.1B
12.71%
0.9%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Illumina beats expectations, history suggests the stock could rise by around 0.69% on the following day, reinforcing positive sentiment.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
A miss could lead to a decline, with historical patterns suggesting a potential drop of around 2.23%.
The lines on the call that would change the story.
Capital World Investors
15,425,298 sh · $4.1B
10.22%
-0.8%
Vanguard Portfolio Management LLC
6,627,157 sh · $1.8B
4.39%
-2.9%
Vanguard Capital Management LLC
6,587,534 sh · $1.8B
4.36%
-0.1%
State Street Corporation
6,507,288 sh · $1.7B
4.31%
1.2%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.